Scientific Program
2020 Antibody Therapeutics Conference:
Antibody Drug Development in the Post-COVID-19 Era and the Strategy of New Generation Antibody Drug Development
Date: 29th October, 2020
Time |
Activities |
Speaker |
10:00-10:30 |
Registration |
|
10:30-10:35 |
Welcome Remarks |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長) |
10:35-10:40 |
Moderator |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長) |
10:40-11:10 |
Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike |
David D. Ho, M.D. (何大一院士) |
11:10-11:40 |
Therapeutic Prospects for SARS-CoV-2 Infection with Cytokine Storm |
Chang-Youh Tsai, M.D., Ph.D. (蔡長祐主任) |
11:40-12:10 |
Potential of human B cell-derived monoclonal antibodies against SARS-CoV-2 spike |
Kuan-Ying Arthur Huang, MD, DPhil. (黃冠穎醫師) |
12:10-12:15 |
Group photo |
|
12:15-13:20 |
Lunch 2nd meeting of the 3rd TAA Board of Directors |
|
13:20-13:30 |
2nd meeting of the 3rd TAA General Assembly |
|
13:30-13:35 |
Moderator |
Wei-Kuang Chi, Ph.D. (紀威光副執行長) |
13:35-14:05 |
Anti-SARS-CoV-2 Monoclonal Antibodies for Diagnosis and Therapy of COVID-19 |
Han-Chung Wu, Ph.D. (吳漢忠主任) |
14:05-14:35 |
The Impact of COVID-19 Pandemic on Biomanufacturing Operations |
Lee-Cheng Liu, Ph.D. (劉理成總經理) |
14:35-14:55 |
Break |
|
14:55-15:00 |
Moderator |
Shih-Chong Tsai, Ph.D. (蔡士昌所長) |
15:00-15:30 |
Current Trend in Antibody-Drug Conjugates and Site-specific Trimannosyl Conjugation platform |
Shih-Hsien Chuang, Ph.D. (莊士賢副所長) |
15:30-16:00 |
Proteomic profiling of antibody-drug conjugate biomarker panel for rational drug design |
Sheeno Thyparambil, Ph.D. |
16:00-16:05 |
Closing Remarks |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長) |
※ The length of a keynote speech is 25 minutes presentation + 5 minutes Q&A.
※ The organizer reserves the right to make changes to the event program.